Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-262 (Saxagliptin) long-term co-administration in T2DM
NCT01193179Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by Kyowa Kirin. Primary endpoint: Adverse events, clinical laboratory tests at 52 weeks. Started Jul 2010; status: completed.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01193179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193179.